» Articles » PMID: 12027425

Detection of Anti-neutrophil Cytoplasmic Antibodies Under Actual Clinical Testing Conditions

Overview
Journal Clin Immunol
Date 2002 May 25
PMID 12027425
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Anti-neutrophil cytoplasmic antibodies (ANCA) are a useful diagnostic tool for Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). To maximize diagnostic utility, current guidelines recommend dual testing by standard indirect immunofluorescence (IIF) and target antigen-specific assays. Most published data come from specialized research laboratories, not reflecting the performance of assays under routine clinical conditions. Therefore, we compared the performance of standard IIF, PR3-, and MPO-ANCA-specific direct ELISA, and a PR3-ANCA-specific capture ELISA used alone and in combination under routine clinical conditions. Consecutive serum samples (615) submitted for routine ANCA testing over a 10-month period were assayed. Diagnoses were WG/MPA (n = 86), other autoimmune disease (n = 118), and various others (n = 411). The combination of PR3-ANCA and MPO-ANCA ELISA had the highest sensitivity (72.1%), and C-ANCA determination using IIF, the highest specificity (99.6%). While maintaining maximal diagnostic accuracy, significant labor savings are achieved by screening for WG/MPA by ELISA followed by confirmatory IIF.

Citing Articles

Activation of a Latent Epitope Causing Differential Binding of Antineutrophil Cytoplasmic Antibodies to Proteinase 3.

Casal Moura M, Thompson G, Nelson D, Fussner L, Hummel A, Jenne D Arthritis Rheumatol. 2022; 75(5):748-759.

PMID: 36515151 PMC: 10191989. DOI: 10.1002/art.42418.


Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Causes Aortic Valve Degeneration and Severe Aortic Regurgitation.

Guterbaum T, Husic M, Voss A, Dahl J Am J Case Rep. 2019; 20:423-429.

PMID: 30930460 PMC: 6454581. DOI: 10.12659/AJCR.912693.


ANCA associated vasculitis: experience of a tertiary care referral center.

Chaudhry R, Bilal A, Austin A, Mehta S, Salman L, Foulke L J Bras Nefrol. 2018; 41(1):55-64.

PMID: 30095143 PMC: 6534033. DOI: 10.1590/2175-8239-JBN-2018-0040.


Chemiluminescent immunoassay technology: what does it change in autoantibody detection?.

Cinquanta L, Fontana D, Bizzaro N Auto Immun Highlights. 2017; 8(1):9.

PMID: 28647912 PMC: 5483212. DOI: 10.1007/s13317-017-0097-2.


Discrepancies between two immunoassays for the determination of MPO and PR3 autoantibodies.

Sun Q, Calderon B, Zhao Z Clin Chim Acta. 2017; 470:93-96.

PMID: 28495147 PMC: 5667675. DOI: 10.1016/j.cca.2017.05.008.